Kwanan nan, Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta sanar da cewa an amince da Encorafenib na wucin gadi don yin bitar fifiko. Za a yi amfani da shi tare da cetuximab da kuma tsarin maganin chemotherapy na FOLFOX a matsayin magani na farko ga manya da ke fama da cutar kansar hanji ta BRAF V600E-mutant.
Wannan yana nuna babban ci gaba a fannin warkewa a cikin al'ummar likitanci ta duniya game da wannan ciwon daji mai wahalar magani wanda wani takamaiman maye gurbi na kwayoyin halitta ke haifarwa.
**Menene Encorafenib kuma me yasa yake da mahimmanci?**
Encorafenib wani maganin hana ƙwayoyin cuta ne mai ƙarfi wanda ke da ATP mai gasa sosai. A taƙaice dai, yana kai hari ga ƙwayoyin cutar kansa waɗanda ke ɗauke da maye gurbi na BRAF V600E, yana hana girma da yaduwa. Idan aka kwatanta da wasu masu hana ƙwayoyin cuta na BRAF da aka amince da su a baya, Encorafenib yana da tsawon aikin pharmacodynamic, ma'ana yana ci gaba da tasiri a jiki na tsawon lokaci mai tsawo.
**Bayanan Asibiti: Shaidar Ingancin Nasara**
A ranar 25 ga Janairu, 2025, *Nature Medicine* ta buga nazarin asibiti na Mataki na 3 na maganin chemotherapy na Encorafenib + Cetuximab + don maganin ciwon daji na hanji mai canzawa na BRAF. Binciken BREAKWATER (NCT04607421) yana da nufin kimanta ingancin encorafenib da cetuximab tare da ko ba tare da maganin chemotherapy na yau da kullun ba ga marasa lafiya da ke fama da ciwon daji na hanji mai canzawa na BRAF V600E. Jimillar marasa lafiya 236 an ware su zuwa rukunin gwaji da kuma 243 ga rukunin kulawa. Sakamakon ya nuna an tabbatar da ƙimar amsawa ta zahiri (cORR) na 60.9% a cikin rukunin gwaji, tare da marasa lafiya 3 sun sami cikakken amsawa (CR), 64 ɓangaren amsawa (PR), da 31 rashin lafiya mai karko (SD). A cikin rukunin kulawa, cORR ya kasance 40.0%, tare da CR 2, 42 PR, da 34 SD. Matsakaicin tsawon lokacin amsawa (DOR) shine watanni 13.9 da watanni 11.1, bi da bi. Ba a iya kimanta matsakaicin rayuwa gaba ɗaya a cikin ƙungiyar gwaji ba, idan aka kwatanta da watanni 14.6 a cikin ƙungiyar da ke kula da cutar.
**Ga Marasa Lafiya na Ƙasashen Duniya: Sashen Kula da Cututtukan Cututtuka na Ƙasa da Ƙasa na Asibitin Beijing na Yankin Kudu yana Ba da Damar Samun Maganin Gaggawa**
Wannan tsarin magani na zamani yanzu ya shiga cikin tsarin bita na farko a China. Ga marasa lafiya na ƙasashen waje - idan kai ko wani ɗan uwa yana neman hanyoyin magani mafi kyau - Sashen Duniya na Asibitin Oncology na Yankin Kudu na Beijing ya himmatu wajen yin aiki a matsayin gada ga fasahar likitanci ta duniya. Muna bin diddigin ci gaban magunguna na ƙasashen duniya kuma muna ba da shawarwari na ƙwararru da taimakon likita ga marasa lafiya da suka cancanta.
**Tuntube Mu Yau Don Fara Tafiyar Fata**
Kada ku jira. Kowace dama ta magani tana da damar canza rayuwarku. Ƙungiyar hidimarmu ta harsuna da yawa a shirye take don ba da shawara, tsara lokacin ganawa, da kuma jagorar likita.
���Layin Sadarwa na Fifiko: 400-880-3716
���Sadarwa Ta Nan Take a WeChat: ID: 17801183037
���Imel:
- Primary: `100085_010@163.com`
- Backup: `myimmnet@163.com`
Za ku iya tuntuɓar mu ta kowace hanya da ke sama. Masu kula da marasa lafiya na ƙasashen duniya za su amsa da sauri don taimakawa wajen tsara bayanan likita, tantance zaɓin magani, da duk wata tambaya game da neman kulawa a Beijing. Sashen Ƙasa da Ƙasa na Asibitin Oncology na Yankin Kudu na Beijing a shirye yake don fuskantar ƙalubalen tare da ku, tare da ƙwarewa da tausayi.
Lokacin Saƙo: Afrilu-23-2026